CN105120886A - 治疗皮肤瘢痕形成的组合物和方法 - Google Patents

治疗皮肤瘢痕形成的组合物和方法 Download PDF

Info

Publication number
CN105120886A
CN105120886A CN201380058533.9A CN201380058533A CN105120886A CN 105120886 A CN105120886 A CN 105120886A CN 201380058533 A CN201380058533 A CN 201380058533A CN 105120886 A CN105120886 A CN 105120886A
Authority
CN
China
Prior art keywords
seqidno
dressing
wound
polypeptide
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380058533.9A
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·兰德
科琳·布罗菲
卡琳·彼得森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CN105120886A publication Critical patent/CN105120886A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN201380058533.9A 2012-09-10 2013-09-10 治疗皮肤瘢痕形成的组合物和方法 Pending CN105120886A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261699160P 2012-09-10 2012-09-10
US61/699160 2012-09-10
US13/829,876 US20140072613A1 (en) 2012-09-10 2013-03-14 Compositions and Methods for Treating Cutaneous Scarring
US13/829876 2013-03-14
PCT/US2013/059060 WO2014040074A2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Publications (1)

Publication Number Publication Date
CN105120886A true CN105120886A (zh) 2015-12-02

Family

ID=50233502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058533.9A Pending CN105120886A (zh) 2012-09-10 2013-09-10 治疗皮肤瘢痕形成的组合物和方法

Country Status (14)

Country Link
US (1) US20140072613A1 (enExample)
EP (1) EP2892546A4 (enExample)
JP (1) JP6247692B2 (enExample)
KR (1) KR102040710B1 (enExample)
CN (1) CN105120886A (enExample)
AU (1) AU2013312120B2 (enExample)
CA (1) CA2884264A1 (enExample)
GB (1) GB2520897B (enExample)
HK (2) HK1210422A1 (enExample)
MX (1) MX368878B (enExample)
NZ (1) NZ705743A (enExample)
RU (2) RU2705211C2 (enExample)
SG (1) SG11201501818VA (enExample)
WO (1) WO2014040074A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709270A (zh) * 2016-03-18 2016-06-29 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
CN108451981A (zh) * 2018-04-21 2018-08-28 洛阳轩智生物科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179A (zh) * 2019-12-19 2020-03-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
CN112074596A (zh) * 2018-02-09 2020-12-11 亥姆霍兹慕尼黑-德国健康与环境研究中心(有限公司) 监测疤痕形成的装置和方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
CA2794189C (en) 2010-03-24 2022-01-11 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP2943564B1 (en) 2013-01-09 2026-03-25 International Stem Cell Corporation Sl327 for use in skin regeneration
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
CA2978941A1 (en) 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
CN104689301A (zh) * 2015-03-27 2015-06-10 吴开刚 一种祛除妊娠纹的药物及其制备方法
US10709702B2 (en) 2015-10-08 2020-07-14 Amd Therapeutics Llc Treatment of skin disorders by topical administration of VEGF inhibitors
JP6815782B2 (ja) * 2016-07-29 2021-01-20 小林製薬株式会社 α−ＳＭＡ産生抑制剤
EP3532071A4 (en) * 2016-10-30 2020-09-02 Sirnaomics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE TO ACTIVATE HUMAN FIBROBLAST AND MYOFIBROBLAST APOPTOSIS
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
EP3675874B1 (en) * 2017-09-01 2023-11-29 Excel Med, LLC Pharmaceuticals composition for treating keloid and uses thereof
US10485755B1 (en) * 2018-02-05 2019-11-26 Wade Cheng Formulation and method for treatment of non-acne scars
WO2019222520A1 (en) * 2018-05-16 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation
US20220202827A1 (en) * 2019-04-08 2022-06-30 The General Hospital Corporation Enhancement of Melanocyte Migration Using ROCK Inhibitors
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
WO2020227738A1 (en) * 2019-05-09 2020-11-12 The University Of Chicago Novel material for skin wound closure and scar prevention
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
WO2021145699A1 (ko) * 2020-01-17 2021-07-22 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
US12360428B2 (en) * 2020-04-13 2025-07-15 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法
CN113143524A (zh) * 2021-04-13 2021-07-23 王伟 一种用于构建微创兔膝关节炎模型的穿刺系统
US20240226233A1 (en) * 2021-05-03 2024-07-11 L&C Bio Co., Ltd. Composition comprising zag-derived peptide for improving scars and keloids
CA3220398A1 (en) * 2021-07-30 2023-02-02 Geoffrey Gurtner Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
KR102696817B1 (ko) * 2023-07-06 2024-08-21 주식회사 아루다 히알루론산, 프로테오글리칸, 글리코사미노글리칸, 아텔로콜라겐, 베타글루칸, 유비퀴논 및 비타민 e를 포함하는 에스테틱 조성물 및 이의 제조 방법
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途
WO2026076246A1 (en) * 2024-10-03 2026-04-09 Frontier Bio Corporation Methods and systems for generating vascularized neurospheres
KR20260090760A (ko) * 2024-12-09 2026-06-17 온바이오 주식회사 봉합자국 및 흉터를 최소화 할 수 있는 재건 미용 시술방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085277A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CN102256613A (zh) * 2008-10-20 2011-11-23 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2200557C1 (ru) * 2001-11-23 2003-03-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н.Федорова Способ лечения гипертрофических и келоидных рубцов
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008109794A2 (en) 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
WO2009038783A1 (en) * 2007-09-19 2009-03-26 Surmodics, Inc. Biocompatible foams, systems, and methods
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2010098760A1 (en) * 2009-02-26 2010-09-02 Hewlett-Packard Development Company, L.P. Void pantographs and methods for generating the same
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011160055A2 (en) * 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
DK2670411T3 (da) 2011-02-02 2019-05-13 Excaliard Pharmaceuticals Inc Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085277A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CN102256613A (zh) * 2008-10-20 2011-11-23 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709270A (zh) * 2016-03-18 2016-06-29 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
CN112074596A (zh) * 2018-02-09 2020-12-11 亥姆霍兹慕尼黑-德国健康与环境研究中心(有限公司) 监测疤痕形成的装置和方法
CN108451981A (zh) * 2018-04-21 2018-08-28 洛阳轩智生物科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179A (zh) * 2019-12-19 2020-03-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
CN110917179B (zh) * 2019-12-19 2021-04-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法

Also Published As

Publication number Publication date
MX368878B (es) 2019-10-21
NZ705743A (en) 2018-08-31
GB2520897A (en) 2015-06-03
GB201505972D0 (en) 2015-05-20
KR102040710B1 (ko) 2019-11-05
WO2014040074A3 (en) 2014-06-26
CA2884264A1 (en) 2014-03-13
WO2014040074A2 (en) 2014-03-13
EP2892546A4 (en) 2016-07-13
HK1210422A1 (en) 2016-04-22
US20140072613A1 (en) 2014-03-13
SG11201501818VA (en) 2015-04-29
RU2015113011A (ru) 2016-11-10
EP2892546A2 (en) 2015-07-15
RU2705211C2 (ru) 2019-11-06
RU2019126644A (ru) 2019-09-19
HK1210414A1 (en) 2016-04-22
JP6247692B2 (ja) 2017-12-13
AU2013312120B2 (en) 2018-04-19
KR20150100615A (ko) 2015-09-02
JP2015533798A (ja) 2015-11-26
GB2520897B (en) 2020-07-01
AU2013312120A1 (en) 2015-03-26
MX2015003075A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
JP6247692B2 (ja) 皮膚瘢痕を治療する組成物及び方法
EP3479831B1 (en) Composition comprising thrombin-treated stem cell-derived exosome for use in treating skin wound
KR101830926B1 (ko) 피부 노화를 방지 및/또는 개선하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
JPH06506205A (ja) 創傷治療
Cho et al. Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers
Galie et al. Reduced serum content and increased matrix stiffness promote the cardiac myofibroblast transition in 3D collagen matrices
JP2017148075A (ja) 創傷治癒組成物および治療
KR20130095835A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
JP2023145532A (ja) 局所皮膚低栄養状態の治療
EP3413881B1 (en) Compositions and methods for treating chronic wounds
KR20080031405A (ko) 상피 재생의 촉진
JP2015513905A (ja) カドヘリン調節に基づく組成物および処置
TWI353849B (en) Methods and compositions for the promotion of hair
JP2017513944A (ja) 異常な皮膚瘢痕化の治療
WO2019080284A1 (zh) 一种药物作用靶点的组合物和应用
WO2018106536A1 (en) Methods for making and using dedifferentiated and stem-like human cells
KR20250058279A (ko) 피부 흉터 형성을 치료하기 위한 조성물 및 방법
JP6469767B2 (ja) 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
KR20210018450A (ko) 비후성 반흔의 형성 억제용 조성물
WO2021241428A1 (ja) エラスチン産生促進剤及び皮膚化粧料
Williamson et al. Relaxin-2 drives regenerative healing and suppresses scar formation
T HE Conjoint 3rd Australasian Wound & Tissue Repair Society and 9th Australasian Society for Dermatology Research Conference Sydney Australia May 22–24, 2012
TW202528538A (zh) 用於皮膚煥新的工程化外泌體
Copenhagen 7th Joint Meeting of the European Tissue Repair Society (ETRS) with the Wound Healing Society
KR20180109285A (ko) Crif1을 함유하는 상처 치료용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20210129

AD01 Patent right deemed abandoned